TSE:HLS HLS Therapeutics (HLS) Stock Price, News & Analysis C$3.99 -0.05 (-1.24%) As of 03/10/2025 03:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider Trades About HLS Therapeutics Stock (TSE:HLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HLS Therapeutics alerts:Sign Up Key Stats Today's RangeC$3.97▼C$4.0250-Day RangeC$3.77▼C$4.2652-Week RangeC$3.00▼C$5.48Volume14,055 shsAverage Volume16,539 shsMarket CapitalizationC$88.77 millionP/E RatioN/ADividend Yield5.01%Price TargetC$4.13Consensus RatingN/A Company OverviewHLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.Read More… Remove Ads Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HLS Stock News HeadlinesTop Canadian Pharmaceutical Stocks of 2025February 3, 2025 | fool.caOptimistic Buy Rating for HLS Therapeutics Despite Revenue ChallengesNovember 10, 2024 | markets.businessinsider.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.March 11, 2025 | Stansberry Research (Ad)HLS Therapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 8, 2024 | finance.yahoo.comHLS Therapeutics Inc (HLTRF) Q3 2024 Earnings Call Highlights: Strategic Debt Reduction and ...November 8, 2024 | finance.yahoo.comHLS Therapeutics Inc (TSX:HLS) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 6, 2024 | finance.yahoo.comHLS Therapeutics Inc. (TSE:HLS) Shares Could Be 38% Below Their Intrinsic Value EstimateOctober 17, 2024 | finance.yahoo.comDantech Announces Participation as a Silver Sponsor at BioFuture 2024 in New York CityOctober 14, 2024 | finance.yahoo.comSee More Headlines HLS Stock Analysis - Frequently Asked Questions How have HLS shares performed this year? HLS Therapeutics' stock was trading at C$3.93 at the beginning of 2025. Since then, HLS stock has increased by 1.5% and is now trading at C$3.99. View the best growth stocks for 2025 here. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) released its earnings results on Thursday, November, 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. HLS Therapeutics had a negative net margin of 38.70% and a negative trailing twelve-month return on equity of 25.27%. How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV). Company Calendar Last Earnings11/07/2024Today3/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:HLS CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price TargetC$4.13 High Stock Price TargetC$5.00 Low Stock Price TargetC$3.25 Potential Upside/Downside+3.4%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-15,528,530.76 Net Margins-38.70% Pretax MarginN/A Return on Equity-25.27% Return on Assets-2.89% Debt Debt-to-Equity Ratio86.50 Current Ratio1.56 Quick Ratio1.01 Sales & Book Value Annual SalesC$40.13 million Price / Sales2.21 Cash FlowC$0.26 per share Price / Cash Flow15.22 Book ValueC$2.51 per share Price / Book1.59Miscellaneous Outstanding Shares22,247,717Free FloatN/AMarket CapC$88.77 million OptionableNot Optionable Beta1.07 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (TSE:HLS) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.